Next
Paradigm
Shift


Humanity VS Diseases 

Why Are We Still Facing Diseases? 


Synthetic biopharmaceuticals have conquered the bio market with great anticipation for the past decades. Biopharmaceuticals have created numerous therapeutics, new treatments to patients with cell & gene therapy.


Unfortunately, there are more than 7,000 rare diseases, and the complexity of these diseases has incapacitated existing treatment methods, and hundreds of millions of patients who have lost the treatment options are suffering.


The onset of the disease is one small factor.

However, once it develops to system-level complexity, it cannot be reversed by simply treating the small factor. 

To overcome this, new innovative therapeutics are needed.


SHIFTBIO wants to use exosomes - a particle that already exist in our body and have evolved along with us, 

and perform complex functions in the body, such as intercellular signal transmission, as a therapeutic agent.


We have developed our own platform technology by maximizing the advantages that only exosomes can perform.


We aim to overcome diseases with high unmet medical needs by developing holistic therapeutics.


SHIFTBIO's exosome platform technology is an infinite power engine that can cure thousands of diseases beyond one disease.


SHIFTBIO will use the strength of exosomes to develop new innovative therapeutics that can provide a second chance to many suffering patients, thereby leading the next paradigm shift in therapeutics.

Next
Paradigm
Shift

Humanity VS Diseases 

Why Are We Still Facing Diseases? 


Synthetic biopharmaceuticals have conquered the bio market with great anticipation for the past decades. Biopharmaceuticals have created numerous therapeutics, new treatments to patients with cell & gene therapy.


Unfortunately, there are more than 7,000 rare diseases, and the complexity of these diseases has incapacitated existing treatment methods, and hundreds of millions of patients who have lost the treatment options are suffering.


The onset of the disease is one small factor.

However, once it develops to system-level complexity, it cannot be reversed by simply treating the small factor. 

To overcome this, new innovative therapeutics are needed.


SHIFTBIO wants to use nanovesicles - a particle that already exist in our body and have evolved along with us, 

and perform complex functions in the body, such as intercellular signal transmission, as a therapeutic agent.


We have developed our own platform technology by maximizing the advantages that only nanovesicles can perform.


We aim to overcome diseases with high unmet medical needs by developing holistic therapeutics.

SHIFTBIO's nanovesicle platform technology is an infinite power engine that can cure thousands of diseases beyond one disease.

SHIFTBIO will use the strength of nanovesicles to develop new innovative therapeutics that can provide a second chance to many suffering patients, thereby leading the next paradigm shift in therapeutics.